FURTRETHONIUM

US Previously Marketed

First approved in 1944

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H14NO
Molecular Weight	140.2029
Optical Activity	NONE
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+](C)(C)CC1=CC=CO1

InChI

InChIKey=HEDXEAAVEOJUCR-UHFFFAOYSA-N

InChI=1S/C8H14NO/c1-9(2,3)7-8-5-4-6-10-8/h4-6H,7H2,1-3H3/q+1

HIDE SMILES / InChI

Molecular Formula	C8H14NO
Molecular Weight	140.2029
Charge	1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18134262 | https://www.ncbi.nlm.nih.gov/pubmed/21019950 | https://www.ncbi.nlm.nih.gov/pubmed/20256338 | https://www.ncbi.nlm.nih.gov/pubmed/9224827

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/122343 https://www.ncbi.nlm.nih.gov/pubmed/20256338 https://www.ncbi.nlm.nih.gov/pubmed/21019950 https://www.ncbi.nlm.nih.gov/pubmed/18134262	Primary		Approved 8583	Furmethide Approved Use Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma

Doses

Dose	Population	Adverse events
10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	Disc. AE: Dacryostenosis acquired... AEs leading to discontinuation/dose reduction: Dacryostenosis acquired (71%) Sources: https://pubmed.ncbi.nlm.nih.gov/14829485

AEs

AE	Significance	Dose	Population
Dacryostenosis acquired	71% Disc. AE	10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14829485	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/14829485

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1W9Q
BOC Sciences	541-64-0
ChemMol	99154117	http://www.chemmol.com/chemmol/99154117.html
eMolecules	109817126
Enamine	BBV-82745797
Enamine	EN300-1588178
MolPort	MolPort-006-111-713
NCI Plated 2007	27126
NCI Plated 2007	44407
NovoSeek	10938
ZINC	ZINC000000001500	http://zinc15.docking.org/substances/ZINC000000001500

PubMed

Title	Date	PubMed
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.	1997-07	9224827
Glaucoma treatment by furnethide and diisopropylfluorophosphate.	1949-07	18134262
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.	1947-08	20256338
Further studies on the use of furmethide in the treatment of glaucoma.	1946-04	21019950

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:14 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:14 GMT 2025`
Record UNII	AIQ630U6XO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FURTRETHONIUM CATION

Preferred Name

English

FURTRETHONIUM

Common Name

English

FURTRIMETHONIUM

Common Name

English

FURTRETHONIUM [MI]

Common Name

English

AMMONIUM, FURFURYLTRIMETHYL-

Systematic Name

English

FURFURYLTRIMETHYLAMMONIUM

Systematic Name

English

2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-

Systematic Name

English

FURTRETONIUM

Common Name

English

FURTRETHONIUM ION

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47792